Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[3]  D. Mannino,et al.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. , 2009, American journal of respiratory and critical care medicine.

[4]  B. Celli,et al.  Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD , 2008, European Respiratory Journal.

[5]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[6]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[7]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[8]  F. Bart,et al.  The Effect of Tiotropium on Hyperinflation and Exercise Capacity in Chronic Obstructive Pulmonary Disease , 2006, Respiration.

[9]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[10]  F. Maltais,et al.  Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. , 2005, Chest.

[11]  M. Decramer,et al.  Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial , 2005, The Lancet.

[12]  B. Celli,et al.  Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[13]  D. O’Donnell,et al.  Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease , 2004, European Respiratory Journal.

[14]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[15]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[16]  R. Zuwallack,et al.  Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.

[17]  Steven Piantadosi,et al.  A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.

[18]  D. O’Donnell,et al.  Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[19]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[20]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[21]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[22]  D. O’Donnell,et al.  Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[23]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[24]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[25]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[26]  D. O’Donnell,et al.  Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. , 1993, The American review of respiratory disease.

[27]  A. Buist,et al.  The Lung Health Study. Baseline characteristics of randomized participants. , 1993, Chest.

[28]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[29]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[30]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.